| Anaplastic Large Cell Lymphoma, ALK-Negative studied in …STUDIED_INderived16 of 16show fewer |
|---|
| → studied in | NCT06724237Phase 3 · recruiting Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729397Phase 1 · not yet recruiting Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176690Phase 1 · recruiting Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03493451Phase 2 · completed Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02561273Phase 1/Phase 2 · completed Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01035463Phase 1/Phase 2 · completed Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04480788Phase 1 · unknown CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075553Phase 2 · terminated Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma · condition mapped ALIAS · 16 trials mapped (6 active) | — | — | Systemic Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02533700Phase 2 · unknown CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL · condition mapped ALIAS · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03040206completed Risk Stratification of Nodal PTCL · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719835Phase 2 · unknown CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01746992Phase 4 · unknown CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma · condition mapped ALIAS · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01198665Phase 1/Phase 2 · completed RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 16 trials mapped (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | Observed | clinicaltrials | graph → |